Ankylosing Spondylitis Clinical Trial
Official title:
The Effects of Tele-Yoga in Ankylosing Spondylitis Patients: A Randomized Controlled Trial
NCT number | NCT04803383 |
Other study ID # | 2021/05-34 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | April 14, 2021 |
Est. completion date | May 30, 2022 |
Verified date | April 2022 |
Source | Dokuz Eylul University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this study is to investigate the effect of tele-yoga on functional level, disease activity, spinal mobility, balance, aerobic capacity, sleep quality, anxiety, depression, stress, mindfulness and quality of life in patients with ankylosing spondylitis
Status | Completed |
Enrollment | 60 |
Est. completion date | May 30, 2022 |
Est. primary completion date | May 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 60 Years |
Eligibility | Inclusion Criteria: - Ankylosing spondylitis(AS) patients diagnosed according to modified New York criteria - To be volunteer - To have the necessary equipment to provide internet access and connection Exclusion Criteria: - Presence of systemic, orthopedic neurological or cognitive disease other than ankylosing spondylitis - Regular exercise in the last 3 months - Pregnancy - Not attending 4 consecutive yoga sessions - Changing the drug during the study - Has an acute attack during the study |
Country | Name | City | State |
---|---|---|---|
Turkey | Dokuz Eylül University | Izmir |
Lead Sponsor | Collaborator |
---|---|
Dokuz Eylul University |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Bath Ankylosing Spondylitis Functional Index (BASFI) | Assess functional capacity. This self-assessment instrument consists of eight specific questions regarding function in AS and two questions reflecting the patient's ability to cope with everyday life regarding function in AS and two questions reflecting the patient's ability to cope with everyday life.The BASFI score is calculated by dividing the sum of the scores from 10 questions by 10. Score range is 0-10, with 0 reflecting no functional impairments and 10 reflecting maximal impairment. | Change from Baseline at 8 weeks | |
Secondary | Bath Ankylosing Spondylitis Spinal Metrology Index (BASMI) | Asses spinal mobility. The total score ranges from 0 to 10. Higher scores mean poor spinal mobility. | Change from Baseline at 8 weeks | |
Secondary | Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) | Assess disease activity. The total score ranges from 0 to 10. High scores mean an increase in disease activity. | Change from Baseline at 8 weeks | |
Secondary | Assessment of Spondyloarthritis international Society Health Index (ASAS HI) | The ASAS HI contains 17 items (dichotomous response option: 'I agree' and 'I do not agree') addressing different aspects of functioning. The total ASAS HI score is between 0 and 17. Lower score indicates a better and a higher score indicates an inferior health status | Change from Baseline at 8 weeks | |
Secondary | Muscular endurance: | Sit-up and push-up tests will be used to evaluate muscular endurance. | Change from Baseline at 8 weeks | |
Secondary | Balance | Balance performance will be assessed by the Balance Master System (NeuroCom® International Inc., USA). | Change from Baseline at 8 weeks | |
Secondary | Aerobic Capacity | The incremental Shuttle Walk Test will be used to determine aerobic capacity | Change from Baseline at 8 weeks | |
Secondary | Pittsburgh Sleep Quality Index | Assess quality of sleep | Change from Baseline at 8 weeks | |
Secondary | The Hospital Anxiety And Depression Scale(HADS) | The HADS is a 14-item self-report questionnaire that measures anxiety (7 items) and depression (7 items) symptoms. | Change from Baseline at 8 weeks | |
Secondary | Stress | Stress will be assessed with Perceived Stress Scale (PSS).The scale consists of 14 items and total score ranges from 0 to 56. High scores indicate high stress perception. | Change from Baseline at 8 weeks | |
Secondary | Mindfulness | Mindful Attention Awareness Scale will be used. The scale consists of 15 items. The total score that can be obtained from the scale is between 15 and 90. High scores reflect more mindfulness. | Change from Baseline at 8 weeks | |
Secondary | Short Form-36 (SF-36) | Assess quality of life | Change from Baseline at 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02685904 -
A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis
|
Phase 3 | |
Completed |
NCT02186873 -
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
|
Phase 3 | |
Completed |
NCT01668004 -
The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)
|
Phase 4 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Completed |
NCT01934933 -
Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis
|
Phase 4 | |
Not yet recruiting |
NCT04875299 -
Optimal Adalimumab Plasma Concentrations in Ankylosing Spondylitis Patients
|
||
Completed |
NCT02763111 -
Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis
|
Phase 2 | |
Completed |
NCT02758782 -
NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis
|
Phase 4 | |
Active, not recruiting |
NCT02687620 -
Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study
|
||
Completed |
NCT02154425 -
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
|
Phase 1 | |
Completed |
NCT01750528 -
Prevalence and Progression of Periodontitis in Ankylosing Spondylitis
|
N/A | |
Completed |
NCT01463189 -
Web-based Support to Manage Arthritis Pain
|
Phase 2 | |
Completed |
NCT01091675 -
Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs
|
Phase 3 | |
Completed |
NCT00844805 -
Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)
|
Phase 3 | |
Recruiting |
NCT00747578 -
Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan
|
N/A | |
Completed |
NCT01083693 -
Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs
|
N/A | |
Completed |
NCT00715091 -
Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis
|
Phase 4 | |
Not yet recruiting |
NCT00517101 -
Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy
|
N/A | |
Completed |
NCT00367211 -
Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.
|
Phase 3 | |
Completed |
NCT00133315 -
TNFalfa Blocking Treatment of Spondylarthropathies
|
Phase 4 |